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Abstract 
BACKGROUND: Familial chronic pemphigus or Hailey-Hailey disease (OMIM 169600) is a rare, autosomal 
dominant blistering skin disorder the genetic background are mutations of the ATP2 C1 gene. The treatment is 
challenging. 
CASE REPORT: A 48-year-old Caucasian female patient presented to the department with a relapse of her 
Pemphigus chronicus familiaris (Hailey-Hailey). No other medical diseases were known. On examination, we 
observed an otherwise healthy woman with widespread erosive lesions on the neck, axillae, groins, submammary 
fold and anal fold. She reported burning sensations and an unpleasant odour. The diagnosis had been confirmed 
earlier by histopathology of a skin biopsy with acantholysis, and the relapsing and remitting course.  Family history 
was positive for father and brother. Since she had not responded well in the past to systemic retinoids and did not 
tolerate the adverse effects of these drugs, we suggested an ablative erbium-YAG laser treatment in general 
anaesthesia. Laser treatment was performed with the MCL 29 Dermablate (Asclepion Laser Technologies, Jena, 
Germany) on two occasions. We used a 5 mm focus, pulse energy of 1200 mJ at 8 Hz. The resulting superficial 
wounds were treated with an ointment containing fusidic acid 0.2% and betamethasone 0.1%. Wound healing was 
completed after 12 days. No adverse events were observed. 
CONCLUSIONS: Ablative erbium-YAG therapy is an option for pemphigus chronicus familiaris, in particular in 
young women and patients who do not tolerate the adverse effects of retinoid therapy. 
 
 
 
 
 
 
Introduction 
 
Familial chronic pemphigus or Hailey-Hailey 
disease (OMIM 169600) is a rare blistering skin 
disorder that affects both sexes equally. It affects the 
skin folds predominantly. The inheritance is autosomal 
dominant. The genetic background is mutations of the 
ATP2 C1 gene encoding for calcium transporter 
protein secretory pathway calcium ATPase SPCA1a 
in the Golgi apparatus [1].  
These mutations are responsible for abnormal 
high cytosolic calcium and magnesium concentration. 
Since there is a functional coupling of SPCA1a and 
Orai1, the store-independent calcium entry becomes 
also affected [2]. 
The genetic findings translate into altered 
protein expression for focal adhesion, extracellular 
matrix receptors, protein digestion and absorption, 
and PI3K-Akt signalling leading to acantholysis and 
disturbed epidermal barrier function [3]. 
The disease causes a significant reduction in 
patients’ quality of life by itching and burning 
sensations, oozing, superinfections and unpleasant 
odour. The course is chronic with frequent relapses 
and rarely longer remissions [4]. Topical treatment 
alone is most often not successful in improving the 
disease. Therefore, many other different treatments 
have been reported in low numbers of patients. 
Acitretin 25 mg/day, etretinate (up to 0.5 mg per kg of 
body weight/day), alitretinoin (30 mg/day) oral steroids 
(variable dosages), dapsone (100-150 mg/d), 
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methotrexate (15 mg/week), cyclosporine 0.2 mg/kg 
body weight/day), glycopyrrolate (1 mg/day), 
afamelanotide (16 mg subcutaneously on day 0 and 
day 30), thalidomide (2 x 100 mg/day), nalotrexone 
(4.5 mg nightly/day), apremilast (3 x 60 mg/day), oral 
vitamin D, botulinum toxin A injections, electron beam 
radiation, photodynamic therapy or dermabrasion [5], 
[6], [7]. 
Another option is ablative laser therapy. Side 
effects are minimal, and costs are lower compared to 
many systemic drugs. We report on erbium-doped 
yttrium aluminium garnet (erbium-YAG) laser therapy 
of familial chronic pemphigus.  
 
 
Case report 
 
A 48-year-old Caucasian female patient 
presented to the department with a relapse of her 
Pemphigus chronicus familiaris (Hailey-Hailey). No 
other medical diseases were known. 
Previously, she had a topical corticosteroid 
ointment with only limited success. On examination, 
we observed an otherwise healthy woman with 
widespread erosive lesions on the neck, axillae, 
groins, submammary fold and anal fold. She reported 
burning sensations and an unpleasant odour. 
The diagnosis had been confirmed earlier by 
histopathology of a skin biopsy with suprabasilar 
acantholysis, eccrine acantholysis, and dyskeratosis. 
There was an upper dermal infiltrate of neutrophils. 
The course was relapsing and remitting. 
Autoantibodies characteristic of autoimmune blistering 
disorders remained negative. Family history was 
positive for father and brother. Lesions remained 
restricted to frictional areas. 
Since she had not responded well in the past 
to systemic retinoids and did not tolerate the adverse 
effects of these drugs, we looked for an alternative. 
Ablative erbium-YAG laser treatment was suggested, 
and a small area on the armpits was treated on a trial 
base. The effect was very good, and the healing was 
fast and uneventful. Therefore, we suggested the 
treatment of larger areas by erbium-YAG laser in 
general anaesthesia. Laser treatment was performed 
with the MCL 29 Dermablate (Asclepion Laser 
Technologies, Jena, Germany) on two occasions. We 
used a 5 mm focus, pulse energy of 1200 mJ at 8 Hz. 
The resulting superficial wounds were treated with an 
ointment containing fusidic acid 0.2% and 
betamethasone 0.1% (Fucicortcreme, Leo 
Pharmaceutical Products Ltd. A/S). Wound healing 
was completed after 12 days (Figure 1). No adverse 
events were observed. 
 
Figure 1: Morbus Hailey-Hailey. Upper row: Before treatment; 
Lower Row: Seven days after ablative laser therapy 
 
 
Discussion 
 
Familial chronic pemphigus resistant to 
conventional therapy may be treated by laser ablation. 
In the past, the only “curative” therapy of the disease 
was excision of lesional skin followed by split-
thickness. The success of surgery is attributed to the 
removal of affected epidermal structures and a 
decrease in sweating and maceration. Laser therapy 
offers a less invasive treatment without the need for 
grafting on treated areas and has a tradition since 
1987 [8]. Reepithelization occurs by hair follicle 
keratinocytes.  
In the case of CO2 laser, 5 to 25 W with 
continuous mode, defocused or pulsed long-term 
improvement or remission have been obtained in the 
majority of patients. However, pain, scarring and 
pigmentary changes are possible adverse effects [9]. 
Alexandrite laser (12-20 J/cm
2
) has been employed 
with up to 13 treatment sessions. Hyperpigmentation 
is a possible adverse event [10]. 
The erbium-YAG laser is a solid-state crystal 
laser. The laser light of 2,940 nm is strongly absorbed 
by water. This prevents the laser cutting of skin and 
extensive scarring [11]. Partial to complete remission 
have been reported after erbium-YAG laser treatment 
during a follow-up of 8 to 12 months [12], [13]. This 
has been confirmed by the present investigation in a 
patient with widespread disease. Laser therapy should 
be considered in such cases. To improve tolerability in 
case of larger areas to be treated, general 
anaesthesia is recommended, while small areas can 
be treated under local anaesthesia.  
The affected epidermis becomes substituted 
by keratinocytes from hair shafts leading to a re-
epithelialization of the superficial wounds. SPCA1 has 
not been identified in hair shaft keratinocytes.  
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